Literature DB >> 20381664

Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry).

James A Reiffel1, Peter R Kowey, Robert Myerburg, Gerald V Naccarelli, Douglas L Packer, Craig M Pratt, Michael J Reiter, Albert L Waldo.   

Abstract

The Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry was designed to examine atrial fibrillation (AF) treatment by United States cardiologists in the context of the American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines after recent landmark clinical trials. Most patients in AFFECTS had AF without clinically significant structural heart disease or only uncomplicated hypertension. Among the all-enrolled population (n = 1,461), initial treatment strategies assigned were rhythm control in 64% and rate control in 36%. Among patients with either paroxysmal (n = 1,165) or persistent (n = 273) AF, 67% and 55%, respectively, were assigned rhythm control. The trend to assign rhythm control as the initial treatment goal decreased with age. In the rhythm-control group, most patients (74%) also received a rate-control agent during the registry, while 25% of those assigned to rate control received antiarrhythmic drugs. Most first prescriptions of antiarrhythmic drugs were for first-line therapy compliant with 2001 (76%) and 2006 (86%) guidelines. Most second prescriptions were for first-line therapies as well. Rates of serious adverse events were low. In conclusion, data from this study provide insight into community treatment patterns in patients with AF, most without clinically significant structural heart disease or with only uncomplicated hypertension. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381664     DOI: 10.1016/j.amjcard.2009.11.046

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

1.  Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation.

Authors:  Nancy M Allen LaPointe; Yuliya Lokhnygina; Gillian D Sanders; Eric D Peterson; Sana M Al-Khatib
Journal:  Am Heart J       Date:  2013-09-24       Impact factor: 4.749

Review 2.  Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review.

Authors:  Ahmad S Hersi; Alawi A Alsheikh-Ali; Mohammad Zubaid; Jassim Al Suwaidi
Journal:  J Saudi Heart Assoc       Date:  2012-08-23

Review 3.  Atrial Fibrillation Symptoms and Sex, Race, and Psychological Distress: A Literature Review.

Authors:  Kelly T Gleason; Saman Nazarian; Cheryl R Dennison Himmelfarb
Journal:  J Cardiovasc Nurs       Date:  2018 Mar/Apr       Impact factor: 2.083

4.  Trends in utilization of management strategies for newly diagnosed atrial fibrillation patients in the United States: 1999 to 2008.

Authors:  Arpit Kashyap; Chenghui Li
Journal:  J Pharm Pract       Date:  2011-11-18

Review 5.  The Concept of "Burden" in Atrial Fibrillation.

Authors:  Gregg F Rosner; James A Reiffel; Kathleen Hickey
Journal:  J Atr Fibrillation       Date:  2012-02-02

6.  Trends in US hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials.

Authors:  William Martin-Doyle; Vidal Essebag; Peter Zimetbaum; Matthew R Reynolds
Journal:  J Cardiovasc Electrophysiol       Date:  2010-11-18

7.  Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF.

Authors:  Benjamin A Steinberg; DaJuanicia N Holmes; Karen Pieper; Larry A Allen; Paul S Chan; Michael D Ezekowitz; James V Freeman; Gregg C Fonarow; Bernard J Gersh; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-04-16

8.  Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.

Authors:  Nancy M Allen LaPointe; Dadi Dai; Laine Thomas; Jonathan P Piccini; Eric D Peterson; Sana M Al-Khatib
Journal:  Am J Cardiol       Date:  2014-11-13       Impact factor: 2.778

9.  Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation.

Authors:  I Vogiatzis; E Papavasiliou; I Dapcevitch; S Pittas; E Koulouris
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

10.  Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Authors:  Benjamin A Steinberg; DaJuanicia N Holmes; Michael D Ezekowitz; Gregg C Fonarow; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Paul Chang; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2013-02-20       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.